Atai Life Sciences N.V. – NASDAQ:ATAI

Add to watchlist

$3.89

+2.61

+203.91%

Market open

Closed in about 6 hours

-16.88%

month

-16.88%

quarter

-17.42%

year

Market Cap	195.48M
Enterprise value	101.26M

P/E	-1.93
EV/Sales	4219.57
EV/EBITDA	-0.46
Price/Sales	11549.20
Price/Book	1.06
PEG ratio	-0.17
EPS	-0.22

Revenue	N/A
EBITDA	-116.05M
Income	-33.80M
Revenue Q/Q	-100%
Revenue Y/Y	2.97%

Profit margin	-941133.33%
Oper. margin	-889941.67%
Gross margin	0%
EBIT margin	-889941.67%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Atai Life Sciences N.V. (NASDAQ:ATAI): Profit margin
Jun 2023	172K	-33.04M	-19210.47%
Sep 2023	87K	44.24M	50855.17%
Dec 2023	18K	-18.29M	-101622.22%
Mar 2024	0	-26.71M

Atai Life Sciences N.V. Financials Estimate

Q Y

Atai Life Sciences N.V. (NASDAQ:ATAI): Analyst Estimates
2025	250K	-139.00M	-55601.47%
2026	30.88M	-124.70M	-403.8%
2027	192.93M	65.91M	34.16%
2028	504.54M	255.72M	50.68%

Analysts Price target
Financials & Ratios estimates

Atai Life Sciences N.V. (NASDAQ:ATAI): Debt to assets
Jun 2023	253595000	37.95M	14.97%
Sep 2023	308220000	39.70M	12.88%
Dec 2023	293478000	49.16M	16.75%
Mar 2024	269121000	45.86M	17.04%

Atai Life Sciences N.V. (NASDAQ:ATAI): Cash Flow
Jun 2023	-22.61M	-22.00M	-100K
Sep 2023	-18.43M	-46.48M	-47
Dec 2023	-21.10M	-189.28K	-8.46M
Mar 2024	-22.57M	11.47M	0

Atai Life Sciences N.V. alternative data

Atai Life Sciences N.V.
Employees

Atai Life Sciences N.V. (NASDAQ:ATAI): Employee count
Aug 2023	133
Sep 2023	133
Oct 2023	133
Nov 2023	133
Dec 2023	133
Jan 2024	133
Feb 2024	133
Mar 2024	133
Apr 2024	133
May 2024	83
Jun 2024	83
Jul 2024	83

Atai Life Sciences N.V.
Hedge Funds Holdings Q3 2022

16.87% +2.81%

of ATAI is owned by hedge funds

84 -7

hedge funds hold ATAI stock

25.97M +4.38M

shares is hold by hedge funds

ATAI hedge funds holdings changes

Atai Life Sciences N.V.
Insider Trading

Atai Life Sciences N.V. (NASDAQ:ATAI): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	11999100	0
Sep 2023	40000	0
Nov 2023	20000	0
Apr 2024	0	124851
May 2024	0	151303

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 May 2024	BRAND FLORIAN officer: See Rema..	Common Shares	151,303	$1.92	$290,502
Sale	2 Apr 2024	JOHNSON ANNE NAGENGAST officer: Chief Financial Officer officer: Chief Financial Officer	Common Shares	27,410	$1.85	$50,709
Sale	2 Apr 2024	RAO SRINIVAS officer: See Rema..	Common Shares	61,640	$1.85	$114,034
Sale	2 Apr 2024	KIRPEKAR SAHIL officer: Chief Business Officer officer: Chief Business Officer	Common Shares	35,801	$1.85	$66,232
Option	14 Mar 2024	JOHNSON ANNE NAGENGAST officer: Chief Financial Officer officer: Chief Financial Officer	Common Shares	100,000	N/A	N/A
Option	14 Mar 2024	JOHNSON ANNE NAGENGAST officer: Chief Financial Officer officer: Chief Financial Officer	Restricted Stock Units	100,000	N/A	N/A
Option	14 Mar 2024	KIRPEKAR SAHIL officer: Chief Business Officer officer: Chief Business Officer	Restricted Stock Units	100,000	N/A	N/A
Option	14 Mar 2024	KIRPEKAR SAHIL officer: Chief Business Officer officer: Chief Business Officer	Common Shares	100,000	N/A	N/A
Option	14 Mar 2024	RAO SRINIVAS officer: See Rema..	Common Shares	175,000	N/A	N/A
Option	14 Mar 2024	RAO SRINIVAS officer: See Rema..	Restricted Stock Units	175,000	N/A	N/A

ATAI insider trading transactions

Atai Life Sciences N.V.
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 11 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 15 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 16 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 30 Mar 2022	Q4 2021 Earnings Call Transcript

ATAI earnings call transcripts

Atai Life Sciences N.V.
Executives

Insider	Age	Compensation
Dr. Srinivas G. Rao M.D., Ph.D. (1969) Co-Founder & Chief Scientific Officer	56	$535,030
Mr. Gregory L. Weaver CPA, M.B.A. (1956) MD & Chief Financial Officer	69	$479,710
Mr. Florian Brand (1987) Co-Founder, MD & Chief Executive Officer	38	$405,020

Atai Life Sciences N.V.
Latest News

Thursday, 14 November 2024
11:37	atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts	proactiveinvestors.com
Wednesday, 13 November 2024
09:22	atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01	proactiveinvestors.com
Tuesday, 12 November 2024
15:51	RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say	proactiveinvestors.com
Wednesday, 2 October 2024
09:21	IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG	globenewswire.com
Wednesday, 4 September 2024
07:00	atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Tuesday, 3 September 2024
14:00	Psychedelic Stock Deep Dive: Atai Life Sciences	seekingalpha.com
Saturday, 17 August 2024
08:25	atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI	proactiveinvestors.com
Wednesday, 14 August 2024
11:11	atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead	proactiveinvestors.com
Tuesday, 13 August 2024
08:49	atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results	proactiveinvestors.com
07:10	atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates	globenewswire.com
Monday, 12 August 2024
12:12	Psychedelic drug contender stocks drop after FDA rejects MDMA treatment	marketwatch.com
Wednesday, 7 August 2024
07:00	atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference	globenewswire.com
Thursday, 11 July 2024
13:02	atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know	zacks.com
07:00	3 Dirt-Cheap Drug Developers With Blockbuster Potential	investorplace.com
Monday, 8 July 2024
07:45	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers	investorplace.com
Saturday, 6 July 2024
07:21	3 Psychedelic Stocks to Ride to the Moon and Beyond	investorplace.com
Tuesday, 2 July 2024
15:43	3 Psychedelic Stocks to Buy on the Dip: Summer 2024	investorplace.com
Saturday, 29 June 2024
10:34	atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI	proactiveinvestors.com
Wednesday, 26 June 2024
07:00	atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference	globenewswire.com
Thursday, 20 June 2024
08:42	atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial	proactiveinvestors.com
07:00	atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a	globenewswire.com
Friday, 7 June 2024
11:09	atai Life Sciences poised for success with rigorous clinical trials	proactiveinvestors.com
Friday, 31 May 2024
07:00	atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference	globenewswire.com
Thursday, 23 May 2024
08:11	atai Life Sciences bolsters board with two new directors	proactiveinvestors.com
08:11	atai Life Sciences bolsters board with two new directors	proactiveinvestors.com
Thursday, 16 May 2024
11:32	atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe	proactiveinvestors.com
11:32	atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe	proactiveinvestors.com
Wednesday, 15 May 2024
09:04	atai Life Sciences boss makes way for co-founder on better first quarter	Proactive Investors
Wednesday, 24 April 2024
08:48	atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression study	Proactive Investors
Wednesday, 17 April 2024
09:16	atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT asset	Proactive Investors

Ideas & Opinions

Seeking Alpha 28 Jul 2025

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
Seeking Alpha 2 Jul 2025

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Seeking Alpha 29 Jan 2025

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Seeking Alpha 29 Nov 2023

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value
Seeking Alpha 1 Sep 2023

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
Seeking Alpha 14 Jul 2023

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
Seeking Alpha 6 Oct 2022

Atai Life Sciences: Decentralized Drug Discovery Platform
Seeking Alpha 11 Aug 2022

COMPASS Pathways And The Trillion Dollar Opportunity
Seeking Alpha 28 Jul 2022

The Growth Potential Of Psychedelics Stocks And ETFs
Seeking Alpha 7 Jul 2022

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Frequently Asked Questions (FAQ)

What's the price of Atai Life Sciences N.V. stock today?

One share of Atai Life Sciences N.V. stock can currently be purchased for approximately $3.89.
When is Atai Life Sciences N.V.'s next earnings date?

Unfortunately, Atai Life Sciences N.V.'s (ATAI) next earnings date is currently unknown.
Does Atai Life Sciences N.V. pay dividends?

No, Atai Life Sciences N.V. does not pay dividends.
How much money does Atai Life Sciences N.V. make?

Atai Life Sciences N.V. has a market capitalization of 195.48M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.76% to 314K US dollars.
What is Atai Life Sciences N.V.'s stock symbol?

Atai Life Sciences N.V. is traded on the NASDAQ under the ticker symbol "ATAI".
What is Atai Life Sciences N.V.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Atai Life Sciences N.V.?

Shares of Atai Life Sciences N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Atai Life Sciences N.V.'s key executives?
Atai Life Sciences N.V.'s management team includes the following people:
- Dr. Srinivas G. Rao M.D., Ph.D. Co-Founder & Chief Scientific Officer(age: 56, pay: $535,030)
- Mr. Gregory L. Weaver CPA, M.B.A. MD & Chief Financial Officer(age: 69, pay: $479,710)
- Mr. Florian Brand Co-Founder, MD & Chief Executive Officer(age: 38, pay: $405,020)
Is Atai Life Sciences N.V. founder-led company?

Yes, Atai Life Sciences N.V. is a company led by its founders Dr. Srinivas G. Rao M.D., Ph.D. and Mr. Florian Brand.
How many employees does Atai Life Sciences N.V. have?

As Jul 2024, Atai Life Sciences N.V. employs 83 workers, which is 38% less then previous quarter.
When Atai Life Sciences N.V. went public?

Atai Life Sciences N.V. is publicly traded company for more then 4 years since IPO on 18 Jun 2021.
What is Atai Life Sciences N.V.'s official website?

The official website for Atai Life Sciences N.V. is atai.life.
How can i contact Atai Life Sciences N.V.?

Atai Life Sciences N.V. can be reached via phone at +49 89 21539035.

Atai Life Sciences N.V.

atai.life

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

+49 89 21539035

Krausenstrasse 9-10
Berlin, 10117

CIK: 0001840904
ISIN: NL0015000DX5
CUSIP: N0731H103